Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2025-03-27 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国邦医药2024年度独立董事述职报告（吴晓明）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2024 by an independent director of a listed company. It details the director's duties, attendance at meetings, oversight of company governance, review of financial and operational matters, and compliance with laws and regulations. The content focuses on the independent director's role, activities, and opinions on company governance and financial reporting, rather than presenting financial statements or audit results themselves. It is a detailed management-related report on governance and oversight activities, not a full annual report, audit report, or earnings release. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports. The document is about the independent director's report on their duties and observations, which is a form of management/board information disclosure.
2025-03-27 Chinese
国邦医药2024年年度股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2024 Annual General Meeting (AGM) materials" for Guobang Pharmaceutical Group Co., Ltd. It contains detailed agenda items for the 2024 AGM, including the review and approval of the 2024 annual report, financial statements, profit distribution plan, appointment of auditors, and remuneration proposals. The document is a comprehensive set of meeting materials prepared for the AGM, including reports and proposals to be discussed and voted on at the meeting. It is not the annual report itself, nor is it a brief announcement or a transcript. The document length (7851 characters) and content indicate it is the meeting materials presented at the AGM. Therefore, the correct classification is AGM Information (AGM-R).
2025-03-27 Chinese
国邦医药关于召开2024年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2024 annual performance briefing (业绩说明会) to be held on April 10, 2025. It mentions that the company's 2024 annual report has already been published on March 28, 2025, and this meeting is intended to explain and discuss the financial results and operational performance with investors. The document does not contain actual financial data or detailed financial statements but rather provides logistical information about the upcoming investor meeting. This fits the definition of an Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, specifically an earnings or performance explanation meeting. The document length is short and it is not a report publication announcement or a regulatory filing. Therefore, the correct classification is Investor Presentation (IP).
2025-03-27 Chinese
国邦医药关于召开2024年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2024 Annual General Meeting (AGM) of Guobang Pharmaceutical Group Co., Ltd. It details the date, voting methods, meeting agenda, and procedural information for shareholders. It does not contain the actual annual report, financial statements, or voting results, but rather serves as an announcement to inform shareholders about the upcoming AGM and the matters to be discussed and voted on. The document length is about 3300 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits the definition of AGM Information (AGM-R).
2025-03-27 Chinese
国邦医药关于2025年度为子公司提供担保额度预计的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Guobang Pharmaceutical Group Co., Ltd. regarding the expected guarantee amount for its subsidiaries in the year 2025. It includes specifics about the guarantee amounts, the subsidiaries involved, financial data of these subsidiaries, the decision-making process, and the board's opinion on the guarantees. The document is not a financial report like an annual or interim report, nor is it a call transcript or audit report. It is a regulatory announcement about financing-related guarantees provided by the company to its subsidiaries, which fits the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive details about financing guarantees, not just a brief notice or report publication announcement. Therefore, the most appropriate classification is CAP with high confidence.
2025-03-27 Chinese
国邦医药对会计师事务所2024年度履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the accounting firm (立信会计师事务所) for the year 2024, specifically related to their audit services for 国邦医药集团股份有限公司. It details the auditor's qualifications, independence, audit procedures, quality control, and risk management. The document references the 2024 annual audit engagement but does not contain the actual audited financial statements or the full annual report itself. It is a standalone audit-related report assessing the auditor's performance and compliance with regulations. Given the content and focus on audit firm evaluation and audit quality, this fits the category of an Audit Report / Information (AR). The document length is 4262 characters, which is sufficient for a detailed audit report but not a full annual report. Therefore, the classification is AR with high confidence. FY 2024
2025-03-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.